Randomized Phase II Study of Combined Epigenetic Therapy: Decitabine Vs. Decitabine and Valproic Acid in MDS and AML

@inproceedings{Issa2008RandomizedPI,
  title={Randomized Phase II Study of Combined Epigenetic Therapy: Decitabine Vs. Decitabine and Valproic Acid in MDS and AML},
  author={Jean Pierre J. Issa and Ryan J. Castoro and Farhad Ravandi-Kashani and Stefan H. Faderl and Xuelin Huang and Elihu Estey and Gautam Borthakur and Gail Morris and Guillermo Garcia-Manero and Hagop M. Kantarjian},
  year={2008}
}
Introduction: Inhibition of DNA methylation (DNMTi) by decitabine (DAC) or azacitidine is a form of epigenetic therapy that is clinically effective in the treatment of MDS and AML. In-vitro, histone deacetylase inhibition (HDACi) following DNA hypomethylation induction results in synergistic enhancement of gene expression activation, but the effects of HDACi on the cell cycle can also interfere with DNTMi activity, resulting in schedule dependent antagonism. Phase I/II studies of the… CONTINUE READING

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS